Aurinia Pharmaceuticals (AUPH) has released an update.
Aurinia Pharmaceuticals Inc. is poised to publish its Q1 financial and operational results for 2024 on May 2, before the market opens. An accompanying conference call and webcast led by the management team will provide a business update following the release. The company, known for introducing the first FDA-approved oral therapy for lupus nephritis, operates globally with a focus on autoimmune diseases.
For further insights into AUPH stock, check out TipRanks’ Stock Analysis page.
